Thus, targeting of IL-17 (the main pro-inflammatory cytokine associated with terminally differentiated Th17 cells) with the therapeutic monoclonal antibodies secukinumab or ixekizumab has proved highly successful in AS (37, 38) and psoriasis (39) but not IBD (40). This evidence concerns the gene IL17A and psoriasis.